Trial Profile

Cross-over Study to Assess the Difference in Fasting Plasma Glucose (FPG) Between Vildagliptin (Galvus/Eucreas) and Sitagliptin (Januvia/Janumet) After Two Weeks.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Mar 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vildagliptin (Primary) ; Sitagliptin
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms FPG-VISIT
Sponsors Novartis; Novartis Pharma

Most Recent Events

19 Sep 2014 Primary endpoint has been met (Fasting plasma glucose level after 14 days of treatment with vildagliptin is superior to sitagliptin), according to the results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
23 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com